<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anesthesia for labor and delivery in high-risk heart disease: General considerations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anesthesia for labor and delivery in high-risk heart disease: General considerations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anesthesia for labor and delivery in high-risk heart disease: General considerations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine W Arendt, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David L Hepner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vincenzo Berghella, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Mark, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3042461744"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Maternal mortality is higher in the United States than any other resource-abundant country and cardiovascular disease is the leading cause [<a href="#rid1">1,2</a>]. Although the incidence of pregnancy among women with congenital heart disease is increasing, the main cause of cardiac death in pregnancy is acquired heart disease, specifically cardiomyopathy, coronary artery disease, and aortic disorders. Pregnancy-related mortality is most common in women over age 40 years and also among Black women [<a href="#rid2">2,3</a>].</p><p>Anesthetic management of the pregnant woman with high-risk cardiovascular disease requires an understanding of the individual patient's cardiac anatomy and pathophysiology; how the physiologic changes associated with pregnancy, labor, and delivery have affected the patient; and the hemodynamic alterations that may be induced by the choices of analgesic or anesthetic techniques. Ideally, an individualized management plan is developed in the antepartum period by the patient’s pregnancy heart team [<a href="#rid4">4-6</a>]. According to the American College of Obstetricians and Gynecologists, a patient’s pregnancy heart team is comprised of obstetric providers, maternal-fetal medicine subspecialists, cardiologists and an anesthesiologist at a minimum [<a href="#rid7">7,8</a>]. Interdisciplinary communication and preparation are critically important since peripartum obstetric and cardiac complications may require rapid intervention.</p><p>This topic will discuss general considerations for anesthetic management of the obstetric patient with high-risk acquired or congenital cardiovascular disease, emphasizing methods to minimize peripartum risk while providing optimal anesthetic care. Considerations for anesthetic management of parturients with specific acquired or congenital heart lesions are discussed in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions"</a>.)</p><p>All other aspects of management of heart disease during pregnancy, including specific cardiac pathology, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles"</a>.)</p><p>Basic anesthetic considerations for obstetric patients also apply to those with cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics"</a> and  <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery"</a> and  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">HEMODYNAMIC CHANGES DURING PREGNANCY, LABOR, AND DELIVERY</span><span class="headingEndMark"> — </span>Understanding the hemodynamic changes related to pregnancy, labor, and delivery is essential so clinicians can anticipate which cardiac conditions predispose to decompensation in the peripartum period, and select appropriate anesthetic monitoring and techniques to minimize this risk [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H499650048"><span class="h2">Antepartum</span><span class="headingEndMark"> — </span>Cardiovascular and hemodynamic changes begin as early as the fourth week of gestation and persist for several months postpartum. Systemic vascular resistance (SVR) decreases, heart rate (HR) increases by 15 to 20 beats/minute, and preload increases due to an increase in blood volume. These changes result in a 30 to 50 percent increase in cardiac output (CO) above baseline. A physiologic dilutional anemia also develops. Cardiovascular and hemodynamic adaptations to normal pregnancy are summarized in the figures  (<a class="graphic graphic_figure graphicRef54685 graphicRef61948 graphicRef55985" href="/z/d/graphic/54685.html" rel="external">figure 1A-C</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a>.)</p><p class="headingAnchor" id="H4148185"><span class="h2">Labor</span><span class="headingEndMark"> — </span>During labor, CO progressively increases due to pain, anxiety, and autotransfusion during contractions. Stroke volume (SV) and HR rise and fall with each contraction, with peaks as high as 30 to 50 percent above prelabor values.</p><p class="headingAnchor" id="H4148202"><span class="h2">Delivery</span><span class="headingEndMark"> — </span>Immediately after either vaginal or cesarean delivery, CO peaks as the evacuated uterus contracts and blood from myometrial veins is autotransfused into the systemic venous system. Also, the contracted uterus lifts off the vena cava, resulting in greater venous blood return to the heart, which increases SV. However, blood loss during and immediately after delivery can counteract these effects.</p><p>After vaginal delivery, CO and SV increased by 59 and 71 percent, respectively, within the first 10 minutes in one study [<a href="#rid10">10</a>]. These increases in CO and SV persist for at least one hour, while HR decreases and blood pressure (BP) remains unchanged [<a href="#rid11">11</a>]. In combination, these factors typically result in unchanged mean arterial pressure (MAP) in the early postpartum period after vaginal delivery. However, patients with heart failure are at increased risk of developing pulmonary edema.</p><p>After cesarean delivery under spinal anesthesia, CO increases by about 25 percent immediately after birth, with partial recovery to pre-cesarean delivery values by the time of fascial closure [<a href="#rid12">12,13</a>].</p><p>In patients with cardiovascular disease, other factors that affect hemodynamic status during and immediately after delivery include the underlying cardiac pathology; heart rate and rhythm; gestational age; anesthetic agents; intravascular fluid status; positioning of the patient; and the route, dose, and choice of uterotonic agents. (See <a class="local">'Effects of drugs commonly used in the labor unit'</a> below.)</p><p class="headingAnchor" id="H1689425706"><span class="h1">PRENATAL ANESTHESIA EVALUATION</span><span class="headingEndMark"> — </span>Prepartum evaluation includes review of the patient's cardiovascular lesions prior to and after reparative procedures, as well as pertinent cardiac testing to determine risk during peripartum care  (<a class="graphic graphic_table graphicRef138473" href="/z/d/graphic/138473.html" rel="external">table 1</a>). Appropriate monitoring, intravascular access, and anesthetic techniques are planned and explained to the patient.</p><p>Risk stratification schemes help identify pregnant women with only mild cardiovascular disease who may safely deliver in a community hospital versus those with high risk who should be transferred to a tertiary care center with maximal resources  (<a class="graphic graphic_table graphicRef138472" href="/z/d/graphic/138472.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef134079" href="/z/d/graphic/134079.html" rel="external">table 3</a>) [<a href="#rid4">4,5,9,14-24</a>]. Patients with pre-existing cardiovascular disease are at particularly high risk if their pregnancy is complicated (eg, multiple gestation, preeclampsia, venous thromboembolism) [<a href="#rid14">14</a>]. Although the majority of pregnant women with cardiovascular disease have favorable outcomes [<a href="#rid25">25,26</a>], some may experience deterioration in cardiopulmonary status before or during labor and delivery, or in the early postpartum state [<a href="#rid22">22,27</a>]. Contingency plans for obstetric complications are developed by the pregnancy heart team (cardiologists, obstetricians, neonatologists, and anesthesiologists) including planning for emergency cesarean delivery, postpartum hemorrhage, and management of cardiopulmonary complications or cardiac arrest [<a href="#rid28">28,29</a>]. For example, peripartum nitric oxide administration or more aggressive therapies such as cardiopulmonary bypass, extracorporeal membrane oxygenation, ventricular assist devices, or urgent cardiac surgical intervention are occasionally necessary to treat cardiovascular events during labor and delivery. (See  <a class="medical medical_review" href="/z/d/html/14184.html" rel="external">"Sudden cardiac arrest and death in pregnancy", section on 'Checklists'</a> and <a class="local">'Emergency cardiac surgery with concomitant cesarean delivery'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h1">OBSTETRIC ISSUES</span></p><p class="headingAnchor" id="H499650377"><span class="h2">Induction of labor</span><span class="headingEndMark"> — </span>In women at high risk of maternal morbidity or mortality during labor or delivery, scheduling induction rather than waiting for spontaneous labor to begin may ensure that appropriate specialists are readily available (eg, cardiologist, maternal-fetal medicine specialist, obstetric anesthesiologist, and neonatologist). High-risk patients are identified on a case-by-case basis using risk stratification guidelines, and the clinical decision to schedule induction of labor versus allowing spontaneous onset of labor is multidisciplinary.</p><p>Induction of labor, if required, is generally safe and usually performed in a conventional manner (eg, cervical ripening with Foley catheter or <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, amniotomy, <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a>) (see  <a class="medical medical_review" href="/z/d/html/4476.html" rel="external">"Induction of labor with oxytocin"</a>). Placement of appropriate maternal monitoring devices (discussed below), intravascular access, and other preparations for analgesia and anesthesia should take place before contractions begin. If an epidural catheter is in place, pain control can be implemented promptly when needed, thus mitigating hemodynamic instability related to the pain and stress of labor.</p><p>Women with significant cardiovascular disease should be placed in a semirecumbent position with a lateral tilt during the intrapartum period. Vital signs should be assessed frequently. Cardiac decompensation may mandate initiation of intensive medical management.</p><p class="headingAnchor" id="H499650398"><span class="h2">Route of delivery</span><span class="headingEndMark"> — </span>Vaginal delivery is generally preferred unless there is an obstetric indication for cesarean delivery. In high-risk cardiac patients, obstetric management of labor and delivery may be modified to accommodate the limitations imposed by cardiac dysfunction. Neuraxial analgesia is generally considered essential. If neuraxial analgesia is not an option, then the advisability of vaginal delivery may need to be reconsidered.</p><p>Maternal <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation with a therapeutic international normalized ratio before delivery is an indication for cesarean delivery because the fetus is also anticoagulated, increasing the risk of fetal intracranial hemorrhage, particularly during vaginal birth [<a href="#rid30">30,31</a>].</p><p>Cesarean delivery is rarely performed solely for a maternal cardiac indication. Exceptions may include aortic dissection, or in some cases, progressive aortic enlargement with ascending aorta diameter &gt;45 mm in a patient with Marfan syndrome since cesarean delivery avoids the repetitive increases in cardiac output (CO) related to contractions and pushing  (<a class="graphic graphic_figure graphicRef79834 graphicRef69056" href="/z/d/graphic/79834.html" rel="external">figure 2A-B</a>) (see  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Marfan syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/8129.html" rel="external">"Heritable thoracic aortic diseases: Pregnancy and postpartum care", section on 'Delivery'</a>). Other cardiovascular disorders that may be managed with cesarean delivery include patients requiring rapid intervention and stabilization. However, the method of delivery is always carefully considered and individualized, as discussed in topics addressing each specific cardiovascular lesion.</p><p class="headingAnchor" id="H734053676"><span class="h3">Vaginal "cardiac delivery"</span><span class="headingEndMark"> — </span>In a maternal "cardiac delivery" with epidural analgesia, fetal descent during the majority of the second stage is accomplished exclusively by uterine contractions without the aid of maternal expulsive efforts. When the fetal head reaches the pelvic floor, a low or outlet operative vaginal delivery (either forceps or vacuum extraction) is performed. This avoids the physiologic changes associated with maternal pushing (eg, Valsalva maneuver or increased intrathoracic pressure resulting in decreased venous return, decreased preload, and decreased CO). An alternative is to avoid the Valsalva maneuver by instructing the patient to push with an open glottis [<a href="#rid32">32,33</a>].</p><p>Some studies indicate that maternal expulsive efforts in cardiac disease are well tolerated, while a prolonged passive second stage and an instrumented vaginal delivery may increase the risk of newborn injury, perineal trauma and maternal hemorrhage [<a href="#rid34">34-36</a>]. Thus, the appropriateness of "cardiac delivery" is controversial. The maternal and fetal risks of operative vaginal delivery relative to the maternal cardiac risk associated with Valsalva maneuvers are individually determined for each patient. (See  <a class="medical medical_review" href="/z/d/html/4474.html" rel="external">"Assisted (operative) vaginal birth"</a>.)</p><p>The anesthesiologist continuously monitors and evaluates maternal hemodynamic tolerance of pushing including pulse oximetry waveform and saturation. This is especially helpful in patients with intracardiac shunts because of the concern for right-to-left shunt with increased intrathoracic pressure (see  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Right-to-left shunting with cyanosis'</a> and  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Left-to-right shuntng'</a>). The resultant decrease in oxygen saturation may stress the fetus. For optimal monitoring, it may be necessary to position the pulse oximetry probe on an earlobe or other area since many women use a handgrip during pushing.</p><p class="headingAnchor" id="H173028183"><span class="h2">Endocarditis prophylaxis</span></p><p class="headingAnchor" id="H1571125837"><span class="h2">Effects of drugs commonly used in the labor unit</span><span class="headingEndMark"> — </span>The following medications are often or routinely used during labor or postpartum [<a href="#rid37">37</a>]. Possible implications for patients with high-risk cardiovascular disease are discussed.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">Oxytocin</a><strong> for labor induction/augmentation or prevention/treatment of postpartum hemorrhage</strong> – Oxytocin decreases mean arterial pressure and total peripheral vascular resistance, and possibly causes slight increase in pulmonary artery pressure [<a href="#rid38">38,39</a>]. These changes need to be considered and oxytocin must be administered cautiously to patients with certain cardiovascular lesions (eg, aortic stenosis, hypertrophic obstructive cardiomyopathy, ischemic heart disease, or aortopathy with risk of dissection), since sudden decompensation can occur when afterload is reduced or heart rate is elevated. In these patients, oxytocin is administered as a dilute solution by continuous intravenous (IV) infusion via an infusion pump at a rate of 2.5 – 7.5 IU/hr for elective cesarean delivery (or 7.5-15 IU/hr for intrapartum cesarean delivery) [<a href="#rid37">37,40</a>]. Importantly, oxytocin should <strong>not</strong> be administered IV as a bolus in patients with cardiovascular disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a><strong> for cervical ripening or treatment of postpartum hemorrhage</strong> – We typically avoid misoprostol in women with a history of vasospastic angina or significant coronary artery disease, unless the benefits are likely to outweigh the risks (eg, uterine atony with hemorrhage). Although vaginal misoprostol has not been shown to affect maternal hemodynamics in healthy women [<a href="#rid41">41</a>], there are very rare reports of cardiovascular events after misoprostol administration [<a href="#rid42">42,43</a>]. The likely cause is coronary vasospasm, as demonstrated with coronary angiography and by successful resuscitation that included administration of <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9203" href="/z/d/drug information/9203.html" rel="external">Carboprost tromethamine</a><strong> for treatment of postpartum hemorrhage</strong> – Carboprost tromethamine is avoided in patients with an intracardiac shunt because it may increase shunting due to side effects that include bronchospasm [<a href="#rid45">45</a>] and alterations in the ventilation/perfusion ratio, resulting in increased intrapulmonary shunt fraction and hypoxemia [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9203" href="/z/d/drug information/9203.html" rel="external">Carboprost tromethamine</a> is also avoided in patients with single-ventricle physiology as it may significantly decrease CO, which could result in significant morbidity or mortality [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">Furthermore, <a class="drug drug_general" data-topicid="9203" href="/z/d/drug information/9203.html" rel="external">carboprost tromethamine</a> may induce hypertension at high doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methergine</strong> <strong>for treatment of postpartum hemorrhage</strong> – Methergine is contraindicated in patients with cardiovascular disease, especially those with systemic, pulmonary, or pregnancy-induced hypertension, because of the following side effects:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vasoconstriction (potentially causing sudden systemic hypertension that can result in stroke, seizure, or myocardial ischemia in patients with hypertension, especially preeclampsia) [<a href="#rid48">48</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coronary vasospasm (potentially causing myocardial infarction in patients with ischemic heart disease)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased pulmonary artery pressure (potentially causing shunt reversal and cyanosis in patients with intracardiac shunts)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">Magnesium sulfate</a><strong> for seizure prophylaxis and neonatal neuroprotection</strong> – Cardiac dysfunction is associated with very high magnesium levels and appears to be secondary to respiratory arrest and hypoxia [<a href="#rid49">49</a>]. Toxicity can be avoided by standard maternal monitoring during magnesium administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-agonists for treatment of preterm labor or prolonged or frequent uterine contractions</strong> – Avoid beta-agonist administration in patients with hypertrophic cardiomyopathy (HCM) since this may cause left ventricular outflow obstruction and decompensation with beta-agonist administration. Beta-agonists should be used cautiously in women with other cardiac lesions, and generally should be avoided in women with heart failure.</p><p></p><p class="bulletIndent1">Adverse reactions after beta-agonist administration are seen in 1 to 10 percent of patients, including tachycardia, hypertension, and palpitations. In &lt;1 percent, side effects include arrhythmia, cardiac arrest, chest pain, hypotension, myocardial infarction, myocardial ischemia, pulmonary edema, and paradoxical bronchospasm. Alternative tocolytics are available. (See  <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">"Inhibition of acute preterm labor"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihypertensive drugs</strong> – Because of preeclampsia clinical trials, antihypertensive agents that are well studied in pregnancy include the calcium channel blocker <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>, the beta-blocker with alpha-blocking activity, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>, the direct arteriolar vasodilator, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> and the centrally acting alpha-2 agonist, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>  (<a class="graphic graphic_table graphicRef55212" href="/z/d/graphic/55212.html" rel="external">table 4</a>). However, at times, though, a rapidly acting IV vasodilator is necessary to decrease SVR  (<a class="graphic graphic_table graphicRef110261" href="/z/d/graphic/110261.html" rel="external">table 5</a>). Because of its rapid onset and offset, a titrated IV infusion of the calcium channel blocker <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a> is a reasonable choice to lower blood pressure (BP) during the antepartum, intrapartum periods  (<a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">table 6</a>). We typically initiate the infusion at 5 mg/hour and titrate it up to 15 mg/hour, waiting approximately ten minutes between dose changes to observe the effects. Another option is an infusion of IV <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">clevidipine</a> if a more rapid and titratable calcium channel blocker is preferred; however, this agent has not been well studied in pregnant patients. In patients with high-risk heart disease, agent selection depends on the specific cardiovascular abnormality. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions"</a>.)</p><p></p><p class="headingAnchor" id="H391931204"><span class="h2">Fluid administration during labor</span><span class="headingEndMark"> — </span>Maintain adequate intravascular volume (preload) and avoid dehydration during labor by allowing intake of moderate amounts of clear fluids throughout labor, as recommended in guidelines published by the American Society of Anesthesiologists [<a href="#rid50">50</a>]. If a laboring patient no longer desires liquids, IV administration of maintenance fluid is initiated at 1 mL/kg per hour and titrated according to clinical assessment of the patient's volume status and hemodynamic response to any fluid boluses.</p><p>Additional fluid administration to treat presumed hypovolemia warrants careful monitoring for signs and symptoms of pulmonary congestion. Avoid aggressive fluid administration, particularly in patients with associated preeclampsia. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Cardiomyopathy associated with preeclampsia'</a>.)</p><p class="headingAnchor" id="H11883858"><span class="h1">GENERAL PRINCIPLES OF ANESTHETIC MANAGEMENT</span></p><p class="headingAnchor" id="H3218989516"><span class="h2">Intravascular catheters</span><span class="headingEndMark"> — </span>Filters are placed on all intravenous (IV) catheters in any patient with a known intracardiac or extracardiac shunt to prevent paradoxical air embolism [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Right-to-left shunting with cyanosis'</a> and  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Left-to-right shuntng'</a>.)</p><p class="headingAnchor" id="H2604223269"><span class="h2">Management of implantable cardioverter defibrillators and pacemakers</span><span class="headingEndMark"> — </span>Patients with cardiovascular disease may have a pacemaker (PM), biventricular PM, and/or implantable cardioverter defibrillator (ICD). For women who are laboring with an ICD, we leave the ICD function on during labor. For emergency cesarean delivery, we leave the ICD on, and we position the dispersive electrode pad ("Bovie pad") for the electrosurgery unit (ESU) on the leg. Although risk of electromagnetic interference (EMI) from the ESU is unlikely during surgery below the level of the umbilicus, we also ensure that a magnet is in the operating room to suspend anti-tachyarrhythmia therapy if necessary. Continuous cardiac monitoring is indicated in these patients [<a href="#rid52">52,53</a>]. Appropriate perioperative management of patients with a PM or ICD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94293.html" rel="external">"Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator", section on 'Intraoperative management'</a>.)</p><p class="headingAnchor" id="H4003994780"><span class="h2">Preparation of vasoactive agents</span><span class="headingEndMark"> — </span>Vasoactive drugs should be prepared in advance, including syringes for bolus administration and infusions for continuous administration. Bolus IV doses of both <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> and <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> should be immediately available, as well as a phenylephrine infusion to be administered at 0.1 to 2 mcg/kg per minute if necessary. Depending on the specific cardiac lesion, other vasodilator, inodilator, inotropic, and/or vasopressor drug infusions should also be readily available  (<a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">table 6</a>). Notably, <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> and <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> are myometrial relaxants; thus, these agents are avoided or used with caution immediately after delivery since they may lead to uterine atony and postpartum hemorrhage. Furthermore, nitroprusside is usually avoided as administration of higher doses may cause fetal cyanide toxicity. (See  <a class="medical medical_review" href="/z/d/html/91654.html" rel="external">"Intraoperative management for noncardiac surgery in patients with heart failure", section on 'Hemodynamic management'</a>.)</p><p class="headingAnchor" id="H2285756632"><span class="h2">Management of arrhythmias</span><span class="headingEndMark"> — </span>In any patients with a history of poorly-tolerated tachyarrhythmias, we place external defibrillator pads to achieve rapid cardioversion or defibrillation. Arrhythmias in the peripartum period are not uncommon in patients with cardiovascular disease. It is important to note that cardioversion or defibrillation is not contraindicated in pregnancy, and fetal intolerance of an arrhythmia, as indicated by fetal bradycardia, is an indication for rapid cardioversion. Management of specific arrhythmias is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13600.html" rel="external">"Supraventricular arrhythmias during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13601.html" rel="external">"Ventricular arrhythmias during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15252.html" rel="external">"Maternal conduction disorders and bradycardia during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias", section on 'Cardioversion during pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H1188687597"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>We employ continuous monitoring with a 5-lead electrocardiogram, pulse oximeter with a visible waveform, and intra-arterial blood pressure (BP) catheter during labor or cesarean delivery for most high-risk cardiac lesions [<a href="#rid5">5,9</a>]. Other standard labor monitoring includes noninvasive blood pressure (NIBP) measurement, tocodynamometry, and fetal heart rate (HR) monitoring.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram</strong> – In all high-risk cardiac patients, a continuous five-lead electrocardiogram (ECG) is monitored for development of arrhythmias, as well as detection of myocardial ischemia in those with ischemic heart disease, aortic stenosis, or hypertrophic cardiomyopathy [<a href="#rid54">54-57</a>]. However, many obstetric nurses are not qualified to interpret ECG monitoring (ie, telemetry). Therefore, it may be necessary to coordinate specialized nursing care for patients at risk during labor. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Ischemic heart disease'</a> and  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Obstructive lesions'</a> and  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Hypertrophic cardiomyopathy (HCM)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulse oximetry</strong> – A continuous pulse oximetry monitor with both audible alarms and visible waveform display should be used. This is particularly important for patients with cyanotic congenital heart disease with right-to-left shunting. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Right-to-left shunting with cyanosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intra-arterial catheter</strong> – We suggest insertion of an intra-arterial catheter for continuous blood pressure (BP) monitoring before needle placement for neuraxial anesthesia or before induction of general anesthesia in most patients with high-risk cardiac disease. Systemic BP is monitored with an intra-arterial catheter so that hypotension can be detected and treated promptly. During labor, moment-to-moment monitoring of arterial BP allows analysis of the effects of uterine contractions and maternal expulsive efforts on overall hemodynamics. Moreover, because of the potential for emergency cesarean delivery, we suggest that the intra-arterial catheter be inserted during labor in any patient who may suffer hemodynamic compromise during induction of general anesthesia. An intra-arterial catheter also facilitates management of vasoactive drug administration and measurement of arterial blood gases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central venous catheter</strong> – Insertion of a central venous catheter (CVC) is not recommended for routine monitoring of intravascular volume status but is prudent if the patient requires vasoactive drug infusions or is at risk for peripartum hemorrhage, as well as for monitoring central venous pressure (CVP).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary artery catheter</strong> – A pulmonary artery catheter (PAC) is rarely indicated in parturients with high-risk cardiac disease. The risk of complications (eg, arrhythmias, incorrect interpretation of data, pulmonary artery rupture) is high in this population because of cardiac conduction and anatomic abnormalities. However, a PAC may be helpful in selected patients (eg, severe pulmonary hypertension requiring titration of pulmonary vasodilatory agents such as nitric oxide). In this situation, the patient may undergo labor and delivery in an intensive care unit (ICU) setting or may undergo cesarean delivery in a cardiovascular operating room rather than on a regular obstetric ward. (See <a class="local">'Emergency cardiac surgery with concomitant cesarean delivery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transesophageal or transthoracic echocardiography </strong>–<strong> </strong>In parturients under general anesthesia, transesophageal echocardiography (TEE) or transthoracic echocardiography (TTE) is indicated to determine the cause of any unexplained persistent or life-threatening circulatory instability (ie, "rescue echo"). (See  <a class="medical medical_review" href="/z/d/html/94296.html" rel="external">"Intraoperative rescue transesophageal echocardiography (TEE)"</a>.)</p><p></p><p class="bulletIndent1">Also, TEE monitoring is the best method to assess cardiac volume status (eg, hypovolemia), as well as regional and global cardiac function during general anesthesia. (See  <a class="medical medical_review" href="/z/d/html/14943.html" rel="external">"Intraoperative transesophageal echocardiography for noncardiac surgery", section on 'Volume status'</a> and  <a class="medical medical_review" href="/z/d/html/14943.html" rel="external">"Intraoperative transesophageal echocardiography for noncardiac surgery", section on 'Ventricular function'</a>.)</p><p></p><p class="headingAnchor" id="H3232790406"><span class="h1">ANALGESIA FOR LABOR</span></p><p class="headingAnchor" id="H77919293"><span class="h2">Neuraxial analgesia for labor</span><span class="headingEndMark"> — </span>We suggest a labor epidural, a dural puncture epidural (see  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)", section on 'Dural puncture epidural analgesia'</a>), or a low-dose combined spinal–epidural (CSE) for most parturients with high-risk cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/89518.html" rel="external">"Epidural and combined spinal-epidural anesthesia: Techniques"</a>.)</p><p>A major physiologic benefit of neuraxial labor analgesia in high-risk cardiac patients is reduction in cardiac output (CO) peaks throughout labor since these increases are largely mediated by catecholamine release due to pain and anxiety. Thus, the epidural should be placed early in labor. Ideally, the epidural block is dense enough to minimize any subsequent pain.</p><p>For patients in active labor with severe pain, CSE using intrathecal opioid without local anesthetic in the intrathecal space may be preferable to an epidural technique alone because of faster onset of analgesia with minimal hemodynamic effects. For patients in early labor who are relatively comfortable, this difference is less important.</p><p>In general, neuraxial approaches are desirable because:</p><p class="bulletIndent1"><span class="glyph">●</span>Excellent analgesia is provided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous infusion of local anesthetic and opioid in the epidural catheter may be titrated to meet the needs of the patient as labor progresses. Dense analgesia can be achieved, thus minimizing catecholamine release.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A passive second stage of labor is possible because the urge to push is diminished. (See <a class="local">'Vaginal "cardiac delivery"'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If urgent cesarean delivery becomes necessary, a surgical block can be established with minimal hemodynamic changes by "dosing up" the epidural catheter with more concentrated local anesthetic (typically 2% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>).</p><p></p><p class="headingAnchor" id="H969356292"><span class="h3">Epidural technique for labor</span></p><p class="bulletIndent1"><span class="glyph">●</span>Perform loss-of-resistance technique with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (rather than air) to avoid paradoxical air embolism, which can occur if the epidural needle is unintentionally placed into an epidural vein in a patient with an intra- or extracardiac shunt.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider a dural puncture epidural technique to potentially increase the reliability and sacral coverage of the block [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate the risks and benefits of administering a test dose via the epidural catheter. (See <a class="local">'Test dose administration'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer a 5 mL dose of the labor epidural solution (eg, 0.04 to 0.125% <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> with 1 to 2 mcg/mL <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) incrementally every five minutes, up to 15 mL. Close monitoring is important to assure adequate labor analgesia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the block remains below T10, and therefore provides inadequate labor analgesia, it is reasonable to administer another 5 to 10 mL of the labor epidural solution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If significant labor pain persists 30 minutes after this bolus, it is likely that the position of the epidural catheter is suboptimal and it should be replaced.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer a continuous infusion of the labor epidural solution at a rate of 6 to 12 mL/hour, titrated to maintain adequate analgesia and avoid hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is reasonable to allow a patient-controlled epidural analgesia button for an additional dose of 4 to 6 mL of the infusion as frequently as every 15 minutes, or an epidural pump equipped with programmed intermittent bolus settings. (See  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)", section on 'Patient-controlled epidural anesthesia'</a> and  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)", section on 'Programmed intermittent epidural bolus'</a>.)</p><p></p><p class="headingAnchor" id="H804330461"><span class="h3">CSE technique for labor</span></p><p class="bulletIndent1"><span class="glyph">●</span>Administer 15 mcg of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> into the intrathecal space. Consider eliminating local anesthetic from the intrathecal dose to decrease the likelihood of hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If intrathecal local anesthetic is utilized, 1.5 to 2.5 mg of intrathecal isobaric <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> is a reasonable dose. An example of a patient who would benefit from intrathecal local anesthetic is a multiparous patient rapidly progressing into the second stage of labor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiate administration of a continuous infusion of the labor epidural solution (eg, 0.04 to 0.125% <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> with 1 to 2 mcg/mL of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) at a rate of 6 to 12 mL/hour, titrated to maintain adequate analgesia and avoid hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If labor pain begins to return as the intrathecal <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> (with or without local anesthetic) wears off, administer 5 to 10 mL of 0.04 to 0.125% <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> with 1 to 2 mcg/mL of fentanyl in the epidural catheter every five minutes, up to 15 mL total. Other options include patient-controlled epidural analgesia, a technique that permits the patient to self-administer a bolus of epidural drug solution, with or without a continuous background infusion or programmed intermittent pump-delivered boluses. (See  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)", section on 'Maintenance of labor epidural analgesia'</a>.)</p><p></p><p class="headingAnchor" id="H1059864016"><span class="h3">Test dose administration</span><span class="headingEndMark"> — </span>In patients with cardiovascular disease, we evaluate the risks and benefits of administration of an epidural test dose to assess the possibility of accidental catheter placement into the intravascular or intrathecal space on a case-by-case basis. Test doses typically contain local anesthetic and <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (eg, 3 mL of 1.5% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> with 1:200,000 epinephrine). (See  <a class="medical medical_review" href="/z/d/html/89518.html" rel="external">"Epidural and combined spinal-epidural anesthesia: Techniques", section on 'Epidural test dose'</a>.)</p><p>Obstetric patients with certain cardiovascular lesions would respond poorly to administration of alpha and beta sympathomimetic agonists (eg, aortic aneurysm or dissection, hypertrophic obstructive cardiomyopathy, or severe mitral or aortic stenosis). Even a small IV dose of <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> may result in catastrophic events (eg, marked tachyarrhythmia or hypertension with resultant cardiovascular deterioration). Thus, epinephrine is avoided in such patients, and only a local anesthetic and an opioid are administered to assess for intravascular or intrathecal placement, using one of the following approaches:</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest administering an initial test dose of 3 mL of 1.5% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> with 25 to 50 mcg <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> to test for unintentional intravascular or intrathecal placement of the catheter. Intravascular placement would be determined by rapid onset of central nervous system (CNS) symptoms due to lidocaine or fentanyl blood concentrations, while intrathecal placement would be determined by the onset of a spinal block within approximately five minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternatively, the first dose of the labor epidural solution can be the "test dose." In this practice, the first 5 mL of the labor epidural solution (eg, 0.04 to 0.125% <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> with 1 to 2 mcg/mL <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) is administered, and the patient is immediately assessed for CNS excitation symptoms (intravascular placement), then subsequently assessed (five minutes later) for motor block (intrathecal placement).</p><p></p><p>Whichever technique is chosen, it is important to note that failure to recognize an intravascular injection prior to fully dosing an epidural could result in <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> toxicity and resultant arrhythmias, circulatory collapse, and cardiac arrest. Equally important, failure to recognize an intrathecal injection prior to fully dosing an epidural could result in a high spinal and resultant hypotension, bradycardia, respiratory insufficiency or apnea, loss of consciousness, and cardiac arrest.</p><p>Either scenario could be catastrophic for any patient, but this is especially true for patients having limited cardiac reserve. Certainly, proceeding with caution with initial dosing of the epidural is of paramount importance. In fact, it is reasonable to consider each subsequent dose of epidural local anesthetic solution to be a "test dose." Thus, we administer epidural doses in 3 to 5 mL increments every five minutes, while asking the patient for signs and symptoms of an intravascular or intrathecal injection. If there is no evidence of sensory block after a full 15 mL epidural dose has been administered, then the epidural should be replaced.</p><p class="headingAnchor" id="H499650452"><span class="h2">Parenteral analgesia for labor</span><span class="headingEndMark"> — </span>Patient-controlled analgesia (PCA) via intravascular opioid infusion with <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> in order to achieve optimal pain control and adequate mitigation of catecholamine release may not be a good alternative for patients with high-risk heart disease. Achieving even moderately effective analgesia may require an opioid dose that suppresses ventilation. The resultant carbon dioxide (CO<sub>2</sub>) retention can cause respiratory acidosis, further catecholamine release, and exacerbation of pulmonary hypertension, arrhythmias, ischemia, or decompensated heart failure.</p><p class="headingAnchor" id="H2426520234"><span class="h1">ANESTHESIA FOR CESAREAN DELIVERY</span></p><p class="headingAnchor" id="H734055903"><span class="h2">Neuraxial anesthesia for cesarean delivery</span><span class="headingEndMark"> — </span>Neuraxial anesthetic techniques are preferred in most patients having cesarean delivery, including those with cardiovascular pathology [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/4480.html" rel="external">"Anesthesia for cesarean delivery"</a>.)</p><p>For most high-risk cardiac patients, a low-dose combined spinal-epidural (CSE) or a slowly titrated epidural anesthetic is reasonable if an intra-arterial catheter has been previously inserted for continuous arterial blood pressure (BP) monitoring.</p><p>Purported benefits of the low-dose CSE technique include a slower onset of the neuraxial block, allowing the anesthesiologist to adequately maintain preload and afterload while still achieving the reliability of an intrathecal local anesthetic block. Although data on utilization for delivery in high-risk cardiac patients are limited, we prefer this technique because of the greater reliability of intrathecal (versus solely epidural) local anesthetics for surgical anesthesia. In a case report including four patients with high-risk cardiovascular disease, CSE performed with an intrathecal dose of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> 4 to 5 mg plus <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> 20 to 25 mcg was safe and effective [<a href="#rid59">59</a>]. Administration of this low intrathecal dose is followed by slow loading of the epidural catheter with local anesthetic (eg, 2% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> without <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>) to achieve a T6 surgical level.</p><p class="headingAnchor" id="H804330475"><span class="h3">Epidural technique for cesarean delivery</span><span class="headingEndMark"> — </span>With or without CSE, placement of the epidural catheter is followed by titration (3 to 5 mL every five minutes) of an agent such as 2% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>. With such titration, as well as appropriate monitoring and vigilance, severe cardiovascular instability is unlikely [<a href="#rid60">60,61</a>]. In patients who may not tolerate sympathomimetic activity, it is important to avoid <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> as an additive to the epidural local anesthetic. (See <a class="local">'Test dose administration'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>In high-risk cardiac patients, especially those with any sort of outflow tract obstruction, place an intra-arterial catheter prior to administration of epidural anesthesia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In cardiac lesions where any sudden decrease in preload or afterload can be disastrous, prepare a <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> infusion so that titrated phenylephrine administration can be immediately initiated to treat hypotension. Other vasopressors (eg, <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a>) should also be readily available, although selection of a specific agent depends on the patient’s underlying cardiac abnormality. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform loss of resistance with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, rather than air, to avoid paradoxical air embolism, which could result in stroke in a patient with an intracardiac shunt.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate the risks and benefits of administering an epinephrine-containing test dose via the epidural catheter. (See <a class="local">'Test dose administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform left uterine displacement immediately after placement of the epidural. Exaggerating the tilt may be necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose the epidural catheter slowly with a local anesthetic without <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (3 to 5 mL every five minutes) until a T6 level is achieved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> 50 to 100 mcg via the epidural catheter is often used as an adjunct to reduce intraoperative pain. It is reasonable to administer 100 mcg of epidural fentanyl after the newborn is delivered, or before delivery if there is no fetal compromise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preservative-free <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> 2 to 3 mg or <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> 1 mg via the epidural catheter provides postoperative analgesia. It is reasonable to administer this dose of opioid after the newborn is delivered. We monitor patients receiving long-acting neuraxial opioids for adequacy of ventilation (eg, respiratory rate and depth of respiration), oxygenation (eg, pulse oximetry), and level of consciousness for 24 hours after administration [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia", section on 'Side effects and complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During onset of the block, crystalloid is administered to prevent hypotension (co-loading). However, overhydration and rapid preloading (eg, 1000 mL of crystalloid) should be avoided in patients with heart failure. In these patients, reduced volumes of crystalloid and slower administration are appropriate during onset of the block (eg, 250 mL increments with monitoring of the patient's hemodynamic and clinical responses to each increment), and administration of a vasopressor agent (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>) may be necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If BP begins to fall, titration of a <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> infusion (0.1 to 2 mcg/kg/minute), phenylephrine boluses (40 to 100 mcg), or <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> boluses (5 to 20 mg) are options to counteract the hemodynamic effects of the surgical neuraxial block. Selection depends upon the patient's heart rate (HR) and the specific cardiovascular lesion, although phenylephrine is usually preferred because of lesser potential for fetal acidosis [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If surgery presses beyond an hour, additional 3 to 5 mL epidural doses of 2% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> will likely be necessary.</p><p></p><p class="headingAnchor" id="H989627079"><span class="h3">CSE technique for cesarean delivery</span><span class="headingEndMark"> — </span>We often select a low-dose sequential CSE for hemodynamically stable, well-hydrated women with high-risk cardiovascular disease undergoing cesarean delivery.</p><p class="bulletIndent1"><span class="glyph">●</span>Administer 2.5 to 5 mg isobaric <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> combined with 15 mcg <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and 0.15 mg preservative-free <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> (or 50 to 100 mcg <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>) into the intrathecal space.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequently, dose the epidural catheter slowly with a local anesthetic without <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (eg, 3 to 5 mL of 2% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> every five minutes), titrated to a T6 level over approximately 20 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With this option, a <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> infusion at 0.5 mcg/kg per minute should be initiated immediately prior to intrathecal injection, particularly in patients at high risk for cardiovascular collapse if vasodilation occurs (eg, hypertrophic cardiomyopathy [HCM]). Phenylephrine is subsequently titrated to keep the patient's BP as close to baseline as possible (the usual range is 0.1 to 2 mcg/kg/minute). Other vasopressors should be readily available if phenylephrine is ineffective (eg, <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> [5 to 20 mg boluses], <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> infusion); however, selection of a specific agent depends on the patient’s underlying cardiac abnormality  (<a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions"</a>.)</p><p></p><p class="headingAnchor" id="H111250254"><span class="h3">Concerns regarding spinal anesthesia for selected lesions</span><span class="headingEndMark"> — </span>We avoid a single-shot spinal neuraxial anesthetic technique due to rapid onset of a sympathectomy with sudden decreases in systemic vascular resistance (SVR) and preload, potentially resulting in life-threatening hypotension in patients with these high-risk cardiovascular lesions:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe aortic stenosis or aortic coarctation. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Obstructive lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe mitral stenosis. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Obstructive lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cyanotic congenital heart disease with right to left shunting. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Right-to-left shunting with cyanosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe dilated cardiomyopathies with low ejection fraction (&lt;30 percent). (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Dilated cardiomyopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Hypertrophic cardiomyopathy (HCM)'</a>.)</p><p></p><p>Some anesthesiologists avoid any neuraxial technique in patients with left ventricular outflow tract obstruction [<a href="#rid64">64</a>]. However, careful and well-monitored epidural anesthesia or low-dose sequential combined spinal anesthesia for cesarean delivery has been reported to be well- tolerated, even in parturients with severe aortic stenosis or hypertrophic cardiomyopathy [<a href="#rid60">60,65</a>].</p><p class="headingAnchor" id="H734055828"><span class="h2">General anesthesia technique for cesarean delivery</span><span class="headingEndMark"> — </span>A general anesthetic is occasionally needed for cesarean delivery in patients with high-risk cardiovascular disease (see  <a class="medical medical_review" href="/z/d/html/4480.html" rel="external">"Anesthesia for cesarean delivery"</a>). The pathophysiology and the desired hemodynamic goals for the patient's specific cardiovascular lesion are considered in selection of anesthetic agents. (See  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions"</a>.)</p><p>All patients are preoxygenated with 100 percent oxygen, and a rapid sequence intubation is typically performed for cesarean delivery. If a very slowly titrated induction is indicated to maintain hemodynamic stability in a patient with high-risk cardiovascular disease, hemodynamic stability should be prioritized above concerns for aspiration, and the induction should proceed slowly. Although the value of cricoid pressure is debatable, we use it in all inductions for cesarean deliveries. (See  <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">"Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Preoxygenation'</a> and  <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">"Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Cricoid pressure during RSII'</a>.)</p><p>A reasonable approach for induction in many patients with cardiovascular disease is use of a short-acting hypnotic (eg, <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">etomidate</a> [0.2 to 0.3 mg/kg], <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> [1 to 2.5 mg/kg], or <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> [1.5 to 2.5 mg/kg, in divided doses, titrated to effect] with <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> boluses [50 to 100 mcg] or phenylephrine infusion [0.1 to 2 mcg/kg/minute]). However, considerations in choosing induction agents vary based on the individual cardiovascular lesion and pregnancy complications. For example, ketamine should be avoided in preeclamptic patients because of the sympathetic stimulation (see  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions", section on 'Cardiomyopathy associated with preeclampsia'</a>). <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">Succinylcholine</a> 1 to 1.5 mg/kg is administered for paralysis.</p><p>Although preinduction treatment with <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (50 to 100 mg) and opioids such as <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> (1 to 2 mcg/kg), is typically avoided in cesarean delivery in order to maximize neonatal respiratory drive at birth, patients with cardiovascular disease may benefit from administration of these agents to blunt the sympathetic response to laryngoscopy and intubation. Maternal hemodynamic stability is the priority, rather than the usual obstetric anesthesia concerns regarding neonatal sedation. If fentanyl and lidocaine are administered as adjunct agents during and after induction, the neonatal team should be notified so that preparations are made for possible respiratory support of the newborn. For some patients, the ultra-short acting agent <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> (1 to 2 mcg/kg) is administered during and after induction to avoid tachycardia without risk of causing prolonged neonatal respiratory depression [<a href="#rid66">66,67</a>]. (See  <a class="medical medical_review" href="/z/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents", section on 'Remifentanil'</a>.)</p><p>For maintenance of general anesthesia, <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">sevoflurane</a> or <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">desflurane</a> is administered at approximately 1 minimum alveolar concentration (MAC) value as tolerated. If desflurane is selected, rapid increases in concentration are avoided, as this may cause tachycardia and pulmonary hypertension. <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">Nitrous oxide</a> (N<sub>2</sub>O) is avoided in all patients prior to delivery, and is not used at all in patients with elevated pulmonary artery pressures or intracardiac shunts. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Inhalation anesthetic agents and techniques'</a>.)</p><p class="headingAnchor" id="H3271189128"><span class="h1">EMERGENCY CARDIAC INTERVENTIONS</span></p><p class="headingAnchor" id="H130133923"><span class="h2">Mechanical circulatory support in pregnancy</span><span class="headingEndMark"> — </span>There are increasing reports of the use of mechanical circulatory support (MCS) such as extracorporeal membrane oxygenation (ECMO), intraaortic balloon pumps, and ventricular assist devices (VADs) in pregnancy, labor, delivery, or during the postpartum period [<a href="#rid68">68-71</a>].</p><p class="headingAnchor" id="H592432428"><span class="h3">Initiation of extracorporeal membrane oxygenation</span><span class="headingEndMark"> — </span>Severe respiratory failure or pulmonary hypertension crisis may necessitate initiation of venovenous or venoarterial extracorporeal membrane oxygenation (ECMO) to improve oxygenation, hypercapnia, and/or shock [<a href="#rid68">68,70,72-80</a>]. Most commonly, venovenous ECMO has been employed to treat respiratory failure (eg, due to influenza or COVID-19 infection) [<a href="#rid81">81</a>]. Venoarterial ECMO has also been used in parturients with pulmonary embolism, cardiac failure, or acute pulmonary hypertensive crisis [<a href="#rid73">73-76,82,83</a>]. In the largest case series that included any type of ECMO used in the United States from 1999 to 2014, 331 obstetric patients and 20,123 nonobstetric patients were identified [<a href="#rid80">80</a>]. The most common indications for ECMO in obstetric patients were sepsis (22.1 percent), cardiomyopathy (16.6 percent), and aspiration pneumonia (9.7 percent). In this series, in-hospital all-cause mortality was lower in obstetric ECMO patients compared with nonobstetric ECMO patients (adjusted odds ratio [aOR] 0.78, 95% CI 0.66-0.93) [<a href="#rid80">80</a>].</p><p>In selected patients at extremely high risk of requiring peripartum ECMO support, venous and arterial micro puncture catheters may be placed prior to delivery to facilitate rapid placement of ECMO cannulas if acute decompensation occurs. Details of ECMO initiation and management, and the role of transesophageal echocardiography (TEE) during insertion are discussed in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">"Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/134279.html" rel="external">"Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/131002.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: The role of transesophageal echocardiography (TEE)"</a>.)</p><p></p><p class="headingAnchor" id="H1938865001"><span class="h3">Insertion of intraaortic balloon pump or ventricular assist device</span><span class="headingEndMark"> — </span>Use of an intra-aortic balloon pump (IAPB) or a ventricular assist device (VAD) as a life-saving option for parturients with acute or end-stage chronic heart failure has become more common [<a href="#rid68">68,70,71,84,85</a>]. Initiation and perioperative management of these devices are discussed in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1482.html" rel="external">"Intraaortic balloon pump counterpulsation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127006.html" rel="external">"Short-term left ventricular mechanical circulatory support: Use of echocardiography during initiation and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/112627.html" rel="external">"Anesthesia for noncardiac surgery in adults with a durable ventricular assist device"</a>.)</p><p></p><p class="headingAnchor" id="H4145220761"><span class="h2">Emergency cardiac surgery with concomitant cesarean delivery</span><span class="headingEndMark"> — </span>Certain acute cardiac events result in life-threatening hemodynamic instability (eg, acute onset of severe mitral or aortic regurgitation [ie, due to endocarditis], acute myocardial infarction, acute prosthetic cardiac valve thrombosis or dysfunction, pulmonary embolism, or ascending aortic dissection). In such cases, immediate cardiovascular surgical intervention with cardiopulmonary bypass (CPB) may be necessary. It is important that the pregnancy does not delay life-saving treatment for the mother. If the fetus is viable, the cardiac surgical procedure may be combined with cesarean delivery.</p><p class="headingAnchor" id="H982832219"><span class="h1">POSTPARTUM CARE</span><span class="headingEndMark"> — </span>The intensity of postpartum monitoring is determined by the patient's underlying cardiovascular disease and any obstetric or cardiac events that occurred during labor and delivery [<a href="#rid5">5</a>]. Women with lesions such as pulmonary hypertension, intracardiac shunt, peripartum cardiomyopathy, or a dilated aorta due to Marfan syndrome are at particularly high risk for morbidity and mortality during the postpartum period [<a href="#rid86">86,87</a>]. Details regarding management of postpartum care in patients with high-risk cardiovascular disease are discussed in separate topics. (See  <a class="medical medical_review" href="/z/d/html/6711.html" rel="external">"Overview of the postpartum period: Normal physiology and routine maternal care"</a> and  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Postpartum care'</a> and  <a class="medical medical_review" href="/z/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Postpartum care'</a>.)</p><p class="headingAnchor" id="H1017497525"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115814.html" rel="external">"Society guideline links: Perioperative cardiovascular evaluation and management"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/131710.html" rel="external">"Society guideline links: Obstetric anesthesia"</a>.)</p><p class="headingAnchor" id="H1184071945"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic changes during pregnancy, labor, and delivery</strong> – Understanding these hemodynamic changes allows the anesthesiologist to anticipate decompensation in the peripartum period in patients with cardiovascular lesions, and to select appropriate anesthetic monitoring and techniques to minimize this risk. (See <a class="local">'Hemodynamic changes during pregnancy, labor, and delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prepartum anesthetic evaluation</strong> – Evaluation includes review of the patient's cardiovascular lesions prior to and after reparative procedures, as well as review of recent cardiac testing. Appropriate monitoring, intravascular access, and anesthetic techniques are planned and explained. (See <a class="local">'Prenatal anesthesia evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles for anesthetic management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravascular catheter filters</strong> – Filters are placed on all intravenous (IV) catheters in any patient with a known intracardiac or extracardiac shunt to prevent paradoxical air embolism</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of ICD or pacemaker</strong> – We leave an implantable cardioverter defibrillator (ICD) on during labor. For emergency cesarean delivery, we leave the ICD on, and we position the dispersive electrode pad on the leg. Although risk of electromagnetic interference (EMI) from the electrosurgery unit (ESU) is unlikely during surgery below the level of the umbilicus, we also ensure that a magnet is in the operating room to suspend anti-tachyarrhythmia therapy if necessary. (See  <a class="medical medical_review" href="/z/d/html/94293.html" rel="external">"Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator", section on 'Intraoperative management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vasoactive agents</strong> – Vasoactive drugs are prepared  (<a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">table 6</a>). Notably, <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> and <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> are typically avoided immediately after delivery since these myometrial relaxants may lead to uterine atony and postpartum hemorrhage. (See <a class="local">'Preparation of vasoactive agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of arrhythmias</strong> – External defibrillator pads for rapid cardioversion or defibrillation if history of poorly tolerated tachyarrhythmias.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring </strong>(see <a class="local">'Monitoring'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Continuous pulse oximetry throughout active labor with a visible and audible waveform.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Telemetry if increased risk for arrhythmias; computerized ST-segment trending if risk for myocardial ischemia.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Intra-arterial catheter for continuous blood pressure (BP) monitoring before induction of general anesthesia or needle placement for neuraxial anesthesia.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other invasive cardiovascular monitoring (eg, central venous catheter [CVP], transesophageal echocardiography [TEE]) may be employed in selected patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuraxial analgesia for labor</strong> – We employ an epidural or combined spinal-epidural (CSE) for most parturients with high-risk heart disease (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In selected patients, techniques for test dose administration are modified to avoid administration of local anesthetic containing <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> as an additive. (See <a class="local">'Epidural technique for labor'</a> above and <a class="local">'CSE technique for labor'</a> above and <a class="local">'Test dose administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anesthesia for cesarean section</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuraxial analgesia</strong> – We employ neuraxial anesthesia with a low-dose CSE or a very slowly titrated epidural anesthetic in most patients having cesarean delivery, including those with cardiovascular pathology (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'CSE technique for cesarean delivery'</a> above and <a class="local">'Epidural technique for cesarean delivery'</a> above.)</p><p></p><p class="bulletIndent2">We avoid single-shot spinal anesthesia for cesarean delivery in selected high-risk patients (eg, severe aortic or mitral stenosis, cyanotic congenital heart disease with right-to-left shunting, dilated cardiomyopathies with severe ventricular dysfunction [ejection fraction &lt;30 percent], hypertrophic cardiomyopathy) because of the potential for life-threatening hypotension due to rapid onset of a sympathectomy with sudden decreases in systemic vascular resistance (SVR) and preload. (See <a class="local">'Concerns regarding spinal anesthesia for selected lesions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General anesthesia</strong> – A general anesthetic is occasionally needed for cesarean delivery in patients with high-risk cardiovascular disease. The pathophysiology and the desired hemodynamic goals for a specific cardiovascular lesion are considered in selection of anesthetic agents. (See <a class="local">'General anesthesia technique for cesarean delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for emergency cardiac intervention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mechanical circulatory support</strong> – Development of cardiorespiratory instability may require initiation of venovenous or venoarterial extracorporeal membrane oxygenation (ECMO) or insertion of an intraaortic balloon pump (IABP) or ventricular assist device (VAD). (See <a class="local">'Mechanical circulatory support in pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac surgical procedure</strong> – Acute cardiac events resulting in life-threatening hemodynamic instability (eg, ascending aortic dissection, acute onset of severe mitral or aortic regurgitation, acute myocardial infarction, prosthetic cardiac valve thrombosis, pulmonary embolism) may necessitate life-saving cardiac surgical intervention for the mother. If the fetus is viable this procedure may be combined with cesarean delivery. (See <a class="local">'Emergency cardiac surgery with concomitant cesarean delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum care</strong> – Intensity of postpartum monitoring is determined by the patient's underlying cardiovascular disease and any obstetric or cardiac events that occurred during labor and delivery. (See <a class="local">'Postpartum care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-Related Mortality in the United States, 2011-2013. Obstet Gynecol 2017; 130:366.</a></li><li class="breakAll">Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health. Pregnancy Mortality Surveillance System. Centers for Disease Control. 2020. Updated February 4, 2021. Available at: https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm#causes (Accessed on July 02, 2021).</li><li><a class="nounderline abstract_t">Briller J, Koch AR, Geller SE. Maternal Cardiovascular Mortality in Illinois, 2002-2011. Obstet Gynecol 2017; 129:819.</a></li><li><a class="nounderline abstract_t">Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39:3165.</a></li><li><a class="nounderline abstract_t">Arendt KW, Lindley KJ. Obstetric anesthesia management of the patient with cardiac disease. Int J Obstet Anesth 2019; 37:73.</a></li><li><a class="nounderline abstract_t">Goeddel LA, Jung YH, Patel P, et al. Analysis of the 2018 American Heart Association/American College of Cardiology Guidelines for the Management of Adults With Congenital Heart Disease: Implications for the Cardiovascular Anesthesiologist. J Cardiothorac Vasc Anesth 2020; 34:1348.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 212 Summary: Pregnancy and Heart Disease. Obstet Gynecol 2019; 133:1067.</a></li><li><a class="nounderline abstract_t">Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association. Circulation 2020; 141:e884.</a></li><li><a class="nounderline abstract_t">Meng ML, Arendt KW. Obstetric Anesthesia and Heart Disease: Practical Clinical Considerations. Anesthesiology 2021; 135:164.</a></li><li><a class="nounderline abstract_t">Ueland K, Hansen JM. Maternal cardiovascular dynamics. II. Posture and uterine contractions. Am J Obstet Gynecol 1969; 103:1.</a></li><li><a class="nounderline abstract_t">Kjeldsen J. Hemodynamic investigations during labour and delivery. Acta Obstet Gynecol Scand Suppl 1979; 89:1.</a></li><li><a class="nounderline abstract_t">Ram M, Lavie A, Lev S, et al. Cardiac hemodynamics before, during and after elective cesarean section under spinal anesthesia in low-risk women. J Perinatol 2017; 37:793.</a></li><li><a class="nounderline abstract_t">Lavie A, Ram M, Lev S, et al. Maternal cardiovascular hemodynamics in normotensive versus preeclamptic pregnancies: a prospective longitudinal study using a noninvasive cardiac system (NICaS™). BMC Pregnancy Childbirth 2018; 18:229.</a></li><li><a class="nounderline abstract_t">Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.</a></li><li><a class="nounderline abstract_t">van Mook WN, Peeters L. Severe cardiac disease in pregnancy, part I: hemodynamic changes and complaints during pregnancy, and general management of cardiac disease in pregnancy. Curr Opin Crit Care 2005; 11:430.</a></li><li><a class="nounderline abstract_t">Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.</a></li><li><a class="nounderline abstract_t">Jastrow N, Meyer P, Khairy P, et al. Prediction of complications in pregnant women with cardiac diseases referred to a tertiary center. Int J Cardiol 2011; 151:209.</a></li><li><a class="nounderline abstract_t">Hayward RM, Foster E, Tseng ZH. Maternal and Fetal Outcomes of Admission for Delivery in Women With Congenital Heart Disease. JAMA Cardiol 2017; 2:664.</a></li><li><a class="nounderline abstract_t">Elkayam U, Goland S, Pieper PG, Silverside CK. High-Risk Cardiac Disease in Pregnancy: Part I. J Am Coll Cardiol 2016; 68:396.</a></li><li><a class="nounderline abstract_t">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:e521.</a></li><li><a class="nounderline abstract_t">Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of Pregnancy in Patients With Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2017; 135:e50.</a></li><li><a class="nounderline abstract_t">Silversides CK, Grewal J, Mason J, et al. Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study. J Am Coll Cardiol 2018; 71:2419.</a></li><li><a class="nounderline abstract_t">Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart 2006; 92:1520.</a></li><li><a class="nounderline abstract_t">Levels of Maternal Care: Obstetric Care Consensus No, 9. Obstet Gynecol 2019; 134:e41.</a></li><li><a class="nounderline abstract_t">Ford AA, Wylie BJ, Waksmonski CA, Simpson LL. Maternal congenital cardiac disease: outcomes of pregnancy in a single tertiary care center. Obstet Gynecol 2008; 112:828.</a></li><li><a class="nounderline abstract_t">Maxwell BG, El-Sayed YY, Riley ET, Carvalho B. Peripartum outcomes and anaesthetic management of parturients with moderate to complex congenital heart disease or pulmonary hypertension*. Anaesthesia 2013; 68:52.</a></li><li><a class="nounderline abstract_t">Goldszmidt E, Macarthur A, Silversides C, et al. Anesthetic management of a consecutive cohort of women with heart disease for labor and delivery. Int J Obstet Anesth 2010; 19:266.</a></li><li><a class="nounderline abstract_t">Abir G, Austin N, Seligman KM, et al. Cognitive Aids in Obstetric Units: Design, Implementation, and Use. Anesth Analg 2020; 130:1341.</a></li><li><a class="nounderline abstract_t">Helviz Y, Einav S. Maternal cardiac arrest. Curr Opin Anaesthesiol 2019; 32:298.</a></li><li><a class="nounderline abstract_t">Stevenson RE, Burton OM, Ferlauto GJ, Taylor HA. Hazards of oral anticoagulants during pregnancy. JAMA 1980; 243:1549.</a></li><li><a class="nounderline abstract_t">Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68:122.</a></li><li><a class="nounderline abstract_t">Barasinski C, Lemery D, Vendittelli F. Do maternal pushing techniques during labour affect obstetric or neonatal outcomes? Gynecol Obstet Fertil 2016; 44:578.</a></li><li><a class="nounderline abstract_t">Parnell C, Langhoff-Roos J, Iversen R, Damgaard P. Pushing method in the expulsive phase of labor. A randomized trial. Acta Obstet Gynecol Scand 1993; 72:31.</a></li><li><a class="nounderline abstract_t">Cauldwell M, Von Klemperer K, Uebing A, et al. Why is post-partum haemorrhage more common in women with congenital heart disease? Int J Cardiol 2016; 218:285.</a></li><li><a class="nounderline abstract_t">Cauldwell M, Cox M, Gatzoulis M, et al. The management of labour in women with cardiac disease: need for more evidence? BJOG 2017; 124:1307.</a></li><li><a class="nounderline abstract_t">Ouyang DW, Khairy P, Fernandes SM, et al. Obstetric outcomes in pregnant women with congenital heart disease. Int J Cardiol 2010; 144:195.</a></li><li><a class="nounderline abstract_t">Heesen M, Carvalho B, Carvalho JCA, et al. International consensus statement on the use of uterotonic agents during caesarean section. Anaesthesia 2019; 74:1305.</a></li><li><a class="nounderline abstract_t">Weis FR Jr, Markello R, Mo B, Bochiechio P. Cardiovascular effects of oxytocin. Obstet Gynecol 1975; 46:211.</a></li><li><a class="nounderline abstract_t">Secher NJ, Arnsbo P, Wallin L. Haemodynamic effects of oxytocin (syntocinon) and methyl ergometrine (methergin) on the systemic and pulmonary circulations of pregnant anaesthetized women. Acta Obstet Gynecol Scand 1978; 57:97.</a></li><li><a class="nounderline abstract_t">Jayasooriya G, Silversides C, Raghavan G, Balki M. Anesthetic management of women with heart failure during pregnancy: a retrospective cohort study. Int J Obstet Anesth 2020; 44:40.</a></li><li><a class="nounderline abstract_t">Ramsey PS, Hogg BB, Savage KG, et al. Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy. Am J Obstet Gynecol 2000; 183:1100.</a></li><li><a class="nounderline abstract_t">Misoprostol: serious cardiovascular events, even after a single dose. Prescrire Int 2015; 24:183.</a></li><li><a class="nounderline abstract_t">Matthesen T, Olsen RH, Bosselmann HS, Lidegaard Ø. [Cardiac arrest induced by vasospastic angina pectoris after vaginally administered misoprostol]. Ugeskr Laeger 2017; 179.</a></li><li><a class="nounderline abstract_t">Owusu KA, Brennan JJ, Perelman A, et al. Nitroglycerin administration during cardiac arrest caused by coronary vasospasm secondary to misoprostol. J Cardiol Cases 2015; 12:166.</a></li><li><a class="nounderline abstract_t">O'Leary AM. Severe bronchospasm and hypotension after 15-methyl prostaglandin F(2alpha) in atonic post partum haemorrhage. Int J Obstet Anesth 1994; 3:42.</a></li><li><a class="nounderline abstract_t">Andersen LH, Secher NJ. Pattern of total and regional lung function in subjects with bronchoconstriction induced by 15-me PGF2 alpha. Thorax 1976; 31:685.</a></li><li><a class="nounderline abstract_t">Secher NJ, Thayssen P, Arnsbo P, Olsen J. Effect of prostaglandin E2 and F2alpha on the systemic and pulmonary circulation in pregnant anesthetized women. Acta Obstet Gynecol Scand 1982; 61:213.</a></li><li><a class="nounderline abstract_t">Abouleish E. Postpartum hypertension and convulsion after oxytocic drugs. Anesth Analg 1976; 55:813.</a></li><li><a class="nounderline abstract_t">McCubbin JM, Sibai BM, Ardella TN, Anderson GD. Cardiopulmonary arrest due to acute maternal hypermagnesaemia. Lancet 1981; 1:1058.</a></li><li><a class="nounderline abstract_t">Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology 2016; 124:270.</a></li><li><a class="nounderline abstract_t">Villablanca PA, Lemor A, So CY, et al. Increased Risk of Perioperative Ischemic Stroke in Patients Who Undergo Noncardiac Surgery with Preexisting Atrial Septal Defect or Patent Foramen Ovale. J Cardiothorac Vasc Anesth 2020; 34:2060.</a></li><li><a class="nounderline abstract_t">Crossley GH, Poole JE, Rozner MA, et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm 2011; 8:1114.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists. Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators: an updated report by the american society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices. Anesthesiology 2011; 114:247.</a></li><li><a class="nounderline abstract_t">Ellis JE, Shah MN, Briller JE, et al. A comparison of methods for the detection of myocardial ischemia during noncardiac surgery: automated ST-segment analysis systems, electrocardiography, and transesophageal echocardiography. Anesth Analg 1992; 75:764.</a></li><li><a class="nounderline abstract_t">Leung JM, Voskanian A, Bellows WH, Pastor D. Automated electrocardiograph ST segment trending monitors: accuracy in detecting myocardial ischemia. Anesth Analg 1998; 87:4.</a></li><li><a class="nounderline abstract_t">Slogoff S, Keats AS, David Y, Igo SR. Incidence of perioperative myocardial ischemia detected by different electrocardiographic systems. Anesthesiology 1990; 73:1074.</a></li><li><a class="nounderline abstract_t">London MJ, Hollenberg M, Wong MG, et al. Intraoperative myocardial ischemia: localization by continuous 12-lead electrocardiography. Anesthesiology 1988; 69:232.</a></li><li><a class="nounderline abstract_t">Chau A, Bibbo C, Huang CC, et al. Dural Puncture Epidural Technique Improves Labor Analgesia Quality With Fewer Side Effects Compared With Epidural and Combined Spinal Epidural Techniques: A Randomized Clinical Trial. Anesth Analg 2017; 124:560.</a></li><li><a class="nounderline abstract_t">Hamlyn EL, Douglass CA, Plaat F, et al. Low-dose sequential combined spinal-epidural: an anaesthetic technique for caesarean section in patients with significant cardiac disease. Int J Obstet Anesth 2005; 14:355.</a></li><li><a class="nounderline abstract_t">Ioscovich AM, Goldszmidt E, Fadeev AV, et al. Peripartum anesthetic management of patients with aortic valve stenosis: a retrospective study and literature review. Int J Obstet Anesth 2009; 18:379.</a></li><li><a class="nounderline abstract_t">Arendt KW, Muehlschegel JD, Tsen LC. Cardiovascular alterations in the parturient undergoing cesarean delivery with neuraxial anesthesia. Expert Rev Obstet Gynecol 2012; 1:59.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists Task Force on Neuraxial Opioids, Horlocker TT, Burton AW, et al. Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. Anesthesiology 2009; 110:218.</a></li><li><a class="nounderline abstract_t">Ngan Kee WD, Lee A, Khaw KS, et al. A randomized double-blinded comparison of phenylephrine and ephedrine infusion combinations to maintain blood pressure during spinal anesthesia for cesarean delivery: the effects on fetal acid-base status and hemodynamic control. Anesth Analg 2008; 107:1295.</a></li><li><a class="nounderline abstract_t">Oxorn D. The risks of central neuraxial anesthesia. Anesthesiology 1998; 88:272.</a></li><li><a class="nounderline abstract_t">Autore C, Brauneis S, Apponi F, et al. Epidural anesthesia for cesarean section in patients with hypertrophic cardiomyopathy: a report of three cases. Anesthesiology 1999; 90:1205.</a></li><li><a class="nounderline abstract_t">Orme RM, Grange CS, Ainsworth QP, Grebenik CR. General anaesthesia using remifentanil for caesarean section in parturients with critical aortic stenosis: a series of four cases. Int J Obstet Anesth 2004; 13:183.</a></li><li><a class="nounderline abstract_t">Ngan Kee WD, Khaw KS, Ma KC, et al. Maternal and neonatal effects of remifentanil at induction of general anesthesia for cesarean delivery: a randomized, double-blind, controlled trial. Anesthesiology 2006; 104:14.</a></li><li><a class="nounderline abstract_t">Carlier L, Devroe S, Budts W, et al. Cardiac interventions in pregnancy and peripartum - a narrative review of the literature. J Cardiothorac Vasc Anesth 2020; 34:3409.</a></li><li><a class="nounderline abstract_t">Cauldwell M, Johnson M, Jahangiri M, Roos-Hesselink J. Cardiac interventions and cardiac surgery and pregnancy. Int J Cardiol 2019; 276:43.</a></li><li><a class="nounderline abstract_t">Cotter EK, Banayan J, Tung A, et al. Trends and Outcomes of Mechanical Circulatory Support in Peripartum Women, 2002-2014: A Nationwide Inpatient Sample Analysis. J Cardiothorac Vasc Anesth 2020; 34:1198.</a></li><li><a class="nounderline abstract_t">Gayam S, Staab J, Shih G, Stoops S. Cesarean delivery in a parturient with a left ventricular assist device. Int J Obstet Anesth 2020; 44:53.</a></li><li><a class="nounderline abstract_t">Lopez BM, Malhamé I, Davies LK, et al. Eisenmenger Syndrome in Pregnancy: A Management Conundrum. J Cardiothorac Vasc Anesth 2020; 34:2813.</a></li><li><a class="nounderline abstract_t">Zhang J, Lu J, Zhou X, et al. Perioperative Management of Pregnant Women With Idiopathic Pulmonary Arterial Hypertension: An Observational Case Series Study From China. J Cardiothorac Vasc Anesth 2018; 32:2547.</a></li><li><a class="nounderline abstract_t">Lankford AS, Chow JH, Jackson AM, et al. Clinical Outcomes of Pregnant and Postpartum Extracorporeal Membrane Oxygenation Patients. Anesth Analg 2021; 132:777.</a></li><li><a class="nounderline abstract_t">Mazzeffi MA, Rao VK, Dodd-O J, et al. Intraoperative Management of Adult Patients on Extracorporeal Membrane Oxygenation: An Expert Consensus Statement From the Society of Cardiovascular Anesthesiologists-Part I, Technical Aspects of Extracorporeal Membrane Oxygenation. Anesth Analg 2021; 133:1459.</a></li><li><a class="nounderline abstract_t">Mazzeffi MA, Rao VK, Dodd-o J, et al. Intraoperative Management of Adult Patients on Extracorporeal Membrane Oxygenation: An Expert Consensus Statement From the Society of Cardiovascular Anesthesiologists--Part II, Intraoperative Management and Troubleshooting. Anesth Analg 2021; (in press).</a></li><li><a class="nounderline abstract_t">Fayad G, Larrue B, Modine T, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure in postpartum woman with rheumatic mitral valve disease: benefit, factors furthering the success of this procedure, and review of the literature. J Extra Corpor Technol 2007; 39:112.</a></li><li><a class="nounderline abstract_t">Naoum EE, Chalupka A, Haft J, et al. Extracorporeal Life Support in Pregnancy: A Systematic Review. J Am Heart Assoc 2020; 9:e016072.</a></li><li><a class="nounderline abstract_t">Wong MJ, Bharadwaj S, Galey JL, et al. Extracorporeal Membrane Oxygenation for Pregnant and Postpartum Patients. Anesth Analg 2022; 135:277.</a></li><li><a class="nounderline abstract_t">Taha B, Guglielminotti J, Li G, Landau R. Utilization and Outcomes of Extracorporeal Membrane Oxygenation in Obstetric Patients in the United States, 1999-2014: A Retrospective Cross-Sectional Study. Anesth Analg 2022; 135:268.</a></li><li><a class="nounderline abstract_t">Balogh JG, Dickinson KJ, Mhyre JM. Extracorporeal Membrane Oxygenation for Obstetric Patients: A New Era. Anesth Analg 2022; 135:264.</a></li><li><a class="nounderline abstract_t">Meng ML, Landau R, Viktorsdottir O, et al. Pulmonary Hypertension in Pregnancy: A Report of 49 Cases at Four Tertiary North American Sites. Obstet Gynecol 2017; 129:511.</a></li><li><a class="nounderline abstract_t">Meng ML, Fu A, Westhoff C, et al. Eisenmenger Syndrome in Pregnancy: When Is It Time for ECMO?: A Case Report. A A Pract 2018; 11:270.</a></li><li class="breakAll">Brar N, Garabedian A, Moshiyakhov M, et al. Peripartum cardiomyopathy and cardiogenic shock supported with percutaneous left ventricular assist device. Cath Lab Digest 2012; 20 http://www.cathlabdigest.com/articles/Peripartum-Cardiomyopathy-Cardiogenic-Shock-Supported-Percutaneous-Left-Ventricular-Assist- (Accessed on June 23, 2016).</li><li><a class="nounderline abstract_t">LaRue S, Shanks A, Wang IW, et al. Left ventricular assist device in pregnancy. Obstet Gynecol 2011; 118:426.</a></li><li><a class="nounderline abstract_t">Dob DP, Yentis SM. UK registry of high-risk obstetric anaesthesia: report on cardiorespiratory disease. Int J Obstet Anesth 2001; 10:267.</a></li><li><a class="nounderline abstract_t">Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005; 102:1133.</a></li></ol></div><div id="topicVersionRevision">Topic 4446 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28697109" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pregnancy-Related Mortality in the United States, 2011-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28697109" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pregnancy-Related Mortality in the United States, 2011-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28383382" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Maternal Cardiovascular Mortality in Illinois, 2002-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165544" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415799" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Obstetric anesthesia management of the patient with cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31494006" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Analysis of the 2018 American Heart Association/American College of Cardiology Guidelines for the Management of Adults With Congenital Heart Disease: Implications for the Cardiovascular Anesthesiologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31022119" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ACOG Practice Bulletin No. 212 Summary: Pregnancy and Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32362133" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34046669" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Obstetric Anesthesia and Heart Disease: Practical Clinical Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5761774" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Maternal cardiovascular dynamics. II. Posture and uterine contractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/290123" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hemodynamic investigations during labour and delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28406485" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiac hemodynamics before, during and after elective cesarean section under spinal anesthesia in low-risk women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898711" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Maternal cardiovascular hemodynamics in normotensive versus preeclamptic pregnancies: a prospective longitudinal study using a noninvasive cardiac system (NICaS™).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479246" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prospective multicenter study of pregnancy outcomes in women with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175029" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe cardiac disease in pregnancy, part I: hemodynamic changes and complaints during pregnancy, and general management of cardiac disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584777" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predictors of pregnancy complications in women with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659773" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prediction of complications in pregnant women with cardiac diseases referred to a tertiary center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28403428" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Maternal and Fetal Outcomes of Admission for Delivery in Women With Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27443437" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High-Risk Cardiac Disease in Pregnancy: Part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24589853" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28082385" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Management of Pregnancy in Patients With Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29793631" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973809" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risks of contraception and pregnancy in heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31348224" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Levels of Maternal Care: Obstetric Care Consensus No, 9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18827125" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Maternal congenital cardiac disease: outcomes of pregnancy in a single tertiary care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121251" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Peripartum outcomes and anaesthetic management of parturients with moderate to complex congenital heart disease or pulmonary hypertension*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194011" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anesthetic management of a consecutive cohort of women with heart disease for labor and delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425259" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cognitive Aids in Obstetric Units: Design, Implementation, and Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31045637" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Maternal cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7359739" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hazards of oral anticoagulants during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6985765" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Maternal and fetal sequelae of anticoagulation during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27568414" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Do maternal pushing techniques during labour affect obstetric or neonatal outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8382428" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pushing method in the expulsive phase of labor. A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240153" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Why is post-partum haemorrhage more common in women with congenital heart disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28218452" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The management of labour in women with cardiac disease: need for more evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19411123" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Obstetric outcomes in pregnant women with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31347151" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : International consensus statement on the use of uterotonic agents during caesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1153152" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiovascular effects of oxytocin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/636863" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Haemodynamic effects of oxytocin (syntocinon) and methyl ergometrine (methergin) on the systemic and pulmonary circulations of pregnant anaesthetized women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32739747" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anesthetic management of women with heart failure during pregnancy: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11084548" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Misoprostol: serious cardiovascular events, even after a single dose</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28648167" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : [Cardiac arrest induced by vasospastic angina pectoris after vaginally administered misoprostol].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30546586" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nitroglycerin administration during cardiac arrest caused by coronary vasospasm secondary to misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636910" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Severe bronchospasm and hypotension after 15-methyl prostaglandin F(2alpha) in atonic post partum haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1013940" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pattern of total and regional lung function in subjects with bronchoconstriction induced by 15-me PGF2 alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6957141" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of prostaglandin E2 and F2alpha on the systemic and pulmonary circulation in pregnant anesthetized women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1033698" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Postpartum hypertension and convulsion after oxytocic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6112438" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cardiopulmonary arrest due to acute maternal hypermagnesaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580836" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32127264" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased Risk of Perioperative Ischemic Stroke in Patients Who Undergo Noncardiac Surgery with Preexisting Atrial Septal Defect or Patent Foramen Ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21722856" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245737" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators: an updated report by the american society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416132" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A comparison of methods for the detection of myocardial ischemia during noncardiac surgery: automated ST-segment analysis systems, electrocardiography, and transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661536" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Automated electrocardiograph ST segment trending monitors: accuracy in detecting myocardial ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2248386" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Incidence of perioperative myocardial ischemia detected by different electrocardiographic systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3407971" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intraoperative myocardial ischemia: localization by continuous 12-lead electrocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28067707" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dural Puncture Epidural Technique Improves Labor Analgesia Quality With Fewer Side Effects Compared With Epidural and Combined Spinal Epidural Techniques: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139497" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Low-dose sequential combined spinal-epidural: an anaesthetic technique for caesarean section in patients with significant cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19733057" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Peripartum anesthetic management of patients with aortic valve stenosis: a retrospective study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cardiovascular alterations in the parturient undergoing cesarean delivery with neuraxial anesthesia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194148" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806043" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized double-blinded comparison of phenylephrine and ephedrine infusion combinations to maintain blood pressure during spinal anesthesia for cesarean delivery: the effects on fetal acid-base status and hemodynamic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9447884" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The risks of central neuraxial anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201694" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Epidural anesthesia for cesarean section in patients with hypertrophic cardiomyopathy: a report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15321399" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : General anaesthesia using remifentanil for caesarean section in parturients with critical aortic stenosis: a series of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394684" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Maternal and neonatal effects of remifentanil at induction of general anesthesia for cesarean delivery: a randomized, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954620" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cardiac interventions in pregnancy and peripartum - a narrative review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287057" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cardiac interventions and cardiac surgery and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31924509" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Trends and Outcomes of Mechanical Circulatory Support in Peripartum Women, 2002-2014: A Nationwide Inpatient Sample Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32799066" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cesarean delivery in a parturient with a left ventricular assist device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32381307" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Eisenmenger Syndrome in Pregnancy: A Management Conundrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29525197" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Perioperative Management of Pregnant Women With Idiopathic Pulmonary Arterial Hypertension: An Observational Case Series Study From China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33591093" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical Outcomes of Pregnant and Postpartum Extracorporeal Membrane Oxygenation Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34559089" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Intraoperative Management of Adult Patients on Extracorporeal Membrane Oxygenation: An Expert Consensus Statement From the Society of Cardiovascular Anesthesiologists-Part I, Technical Aspects of Extracorporeal Membrane Oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intraoperative Management of Adult Patients on Extracorporeal Membrane Oxygenation: An Expert Consensus Statement From the Society of Cardiovascular Anesthesiologists--Part II, Intraoperative Management and Troubleshooting</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17672195" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Extracorporeal membrane oxygenation in severe acute respiratory failure in postpartum woman with rheumatic mitral valve disease: benefit, factors furthering the success of this procedure, and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32578471" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Extracorporeal Life Support in Pregnancy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35122684" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Extracorporeal Membrane Oxygenation for Pregnant and Postpartum Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34724684" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Utilization and Outcomes of Extracorporeal Membrane Oxygenation in Obstetric Patients in the United States, 1999-2014: A Retrospective Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35839497" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Extracorporeal Membrane Oxygenation for Obstetric Patients: A New Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28178055" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pulmonary Hypertension in Pregnancy: A Report of 49 Cases at Four Tertiary North American Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29894348" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Eisenmenger Syndrome in Pregnancy: When Is It Time for ECMO?: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29894348" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Eisenmenger Syndrome in Pregnancy: When Is It Time for ECMO?: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768842" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Left ventricular assist device in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15321583" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : UK registry of high-risk obstetric anaesthesia: report on cardiorespiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915025" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
